MarginsXMarginsX
Home › Markets › Health Care › INMB

INmune Bio Inc. (INMB)

INMB trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.9464
-9.87% on the day
Market cap
$29.3M
Nano cap
Revenue · 2025
$50K
+257.1% on 2024
Net income · 2025
-$45.9M
-91866.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/0001213900-26-036370-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerINMB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2019
SEC CIK0001711754
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inNV

Financials · 2025

LineValue
Revenue$50K
Net income-$45.9M
Operating income-$47.4M
Net margin-91866.0%
Operating margin-94766.0%
Revenue growth+257.1%
Cash$24.8M
Total assets$32.4M
P/E (computed)Net income was not positive
P/S (computed)586.0×

Warning signs

Cash runway
15.2 months
$16.3M cash at September 30, 2026
Share count, 1 year
+16.5%
2025-10-30 to 2026-11-05 · +71.8% over 3 years
Going-concern doubt
Yes
10-Q filed November 5, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. 6 In response to these conditions, management is currently evaluating different strategies to obtain the required funding of future operations."
10-Q 2026-11-05
Cash and burn$16.3M cash; operating cash flow -$3.2M a quarter.Report 2026-09-30
Shares outstanding30,959,079 (2026-11-05); 26,585,258 a year earlier; 18,021,692 three years earlier.Cover page 2026-11-05
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-10-29
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCBIZ CPAs P.C., Houston, Texas, United States; changed auditors 1 time in 24 months8-K 4.01 2025-05-07
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$4.7M-$3.4M$16.3MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
Not filed-$1.3M-$3.2M$18.4MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2026
2026-03-31
Not filed-$5.4M-$3.4M$21.4MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-12-31
$0-$5.3M-$2.9M$24.8MNo debt tags$50K10-K 2026-03-30
Q3 2025
2025-09-30
$0-$6.5M-$5.4M$27.7MNo debt tags$50K10-Q 2026-11-05
Q2 2025
2025-06-30
$0-$24.5M-$7.4M$33.4M$15.0M$50K10-Q 2026-08-06
Q1 2025
2025-03-31
$50K-$9.7M-$6.8M$19.3M$15.0M$50K10-Q 2026-05-07
Q4 2024
2024-12-31
$0-$9.2M-$11.0M$20.9M$15.0M$14K10-K 2026-03-30

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS SUPPLEMENT
424B52026-10-29
Latest annual report
ANNUAL REPORT
10-K2026-03-30
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-05
Latest current report
CURRENT REPORT
8-K2026-10-29
Latest proxy
PROXY STATEMENT
DEF 14A2026-04-23

Source: SEC EDGAR submissions feed, 602 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-7.1%
1 month-37.5%
3 months-49.5%
Year to date-32.7%
1 year-26.6%
From 52-week high-58.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
CVMCel-Sci Corporation$1.66+29.69%$29.2M
SAENGenenta Science S.p.A.$0.6000-7.66%$28.9M
LONALeonaBio Inc.$3.23-6.92%$30.4M
PTHSPelthos Therapeutics Inc.$7.15-3.90%$28.1M
MGXMetagenomi Therapeutics Inc.$0.6800-1.69%$25.7M
EVAXEvaxion A/S American Depositary Share$2.77+0.54%$25.5M
KLRSKalaris Therapeutics Inc.$1.46-7.30%$34.8M
ELUTElutia Inc.$0.8229+0.35%$36.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier